In this study, the cardiac function of DCM mice treated with the specific HDAC3 inhibitor, RGFP966, was better than that of those treated with the pan-HDAC inhibitor, valproic acid. The gene discussed is HDAC9; the disease is familial dilated cardiomyopathy.